Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.02.01.478610

Metabolic predictors of phenotypic traits can replace and complement measured clinical variables in transcriptome-wide association studies

Niehues, A.·Bizzarri, D.·Reinders, M. J. T.·Slagboom, P. E.·van Gool, A. J.·van den Akker, E. B.·Hoen, P.-B. t.
View original source ↗Export metadata ↓

Abstract

Transcriptome-wide association studies (TWAS) can provide valuable insights into biological and disease-underlying mechanisms. For studying clinical effects, availability of (confounding) phenotypic traits is essential. The (re)use of RNA-seq or other omics data can be limited by missing, incomplete, or inaccurate phenotypic information. A possible solution are molecular predictors inferring clinical or behavioral phenotypic traits. Such predictors have been developed based on different omics data types and are being applied in various studies. In this study, we applied 17 metabolic predictors to infer various traits, including diabetes status or exposure to lipid medication. We evaluated whether these metabolic surrogates can be used as an alternative to reported information for studying the respective phenotypes using TWAS. Our results revealed that in most cases, the use of metabolic surrogates yields similar results compared to using reported information, making them suitable substitutes for such studies. The application of metabolomics-derived surrogate outcomes opens new possibilities for reuse of multi-omics data sets, especially in situations where availability of clinical metadata is limited. Missing or incomplete information can be complemented by these surrogates, thereby increasing the size of available data sets. Studies would likely also benefit from the use of such surrogates to correct for potential biological confounding. This should be further investigated. Author summaryTranscriptome-wide association studies (TWAS) can be used to associate gene expression levels with phenotypic traits. These associations can provide insights into biological mechanisms including those that underlie diseases. Such studies require molecular profiling data from a large number of individuals as well as information on the phenotypic trait of interest. Biobanks that collect samples and corresponding molecular data, also collect information on phenotypic traits or clinical information. However, this information can be heterogeneous and/or incomplete, or a certain piece of information could be missing entirely. In this study, we apply metabolic predictors to infer various traits, including diabetes status or exposure to lipid medication. We evaluate whether these metabolic surrogates can be used as an alternative to reported information for studying the respective phenotypes using TWAS. Our results reveal that in many cases, the use of metabolic surrogates yields similar results compared to using reported information, making them suitable substitutes for such studies. The possibility of using these surrogate outcomes can thus increase the size of data sets for studies where phenotypic information is incomplete or missing.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Niehues, A., Bizzarri, D., Reinders, M. J. T., Slagboom, P. E., van Gool, A. J., van den Akker, E. B., Hoen, P.-B. t.. 2022-02-02. Metabolic predictors of phenotypic traits can replace and complement measured clinical variables in transcriptome-wide association studies. https://doi.org/10.1101/2022.02.01.478610

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Uncovering Viral Signals Across Cell Populations in Colorectal Cancer

Viral sequences have been detected in colorectal cancer, but their cellular and anatomical distribution remains poorly resolved. We aimed to establish a cell-type-resolved map of viral reference-associated RNA signals across colorectal cancer, tumour-adjacent normal tissue, and healthy colon. We repurposed human-unmapped reads from single-cell RNA sequencing libraries generated in ten publicly available studies. We retained cell-barcode and unique molecular identifier information, removed duplicate molecules, and aligned reads to a curated human-associated viral reference using three aligners. Viral signals were analysed across cell types, tissue conditions, and colorectal segments. We used participant-grouped repeated cross-validation to evaluate tissue-condition classification and screened an independent paired colorectal cancer proteomics cohort for compatible peptide matches. The study included 547 libraries from 112 participants, including 49 with matched colorectal cancer and tumour-adjacent normal samples, and approximately 415,000 cells spanning ten major cell populations. Viral reference-associated RNA signals differed across epithelial, immune, stromal, and vascular compartments, tissue conditions, and anatomical regions of the colon. Of 318 independent healthy-reference viral-load comparisons, seven involving six virus-cell-type groups remained significant after Benjamini-Hochberg correction, including plasma-cell HHV-7 and HHV-6B and mast-cell HCV-2. Cell-type-resolved viral features distinguished colorectal cancer, tumour-adjacent normal tissue, and healthy colon in participant-grouped validation; random forest achieved a macro-AUC of 0.957 (SD 0.028), with HERV-K113 as the leading quantitative feature. An independent proteomic screen identified peptide matches compatible with 20 candidate viral groups. We established a cell-type-resolved map of viral reference-associated RNA signals across colorectal tissue conditions and anatomical regions. By identifying candidate viral signals in epithelial and immune compartments, this map provides a basis for investigating virus-host pathways involved in tumour biology, immune regulation, and antigen-presentation states, and could help prioritise future combination strategies pairing virus-directed or virus-mimetic approaches with standard treatment or immune checkpoint blockade.

bioinformatics↗
bioRxiv2026

Statistical significance testing for spatial domain detection in spatial transcriptomics

In spatial transcriptomics, domain-detection methods group platform-specific spatial measurement units--cells, bins or multicellular spots--into spatial domains for comparing molecular programs, cellular composition and interactions among tissue regions. However, the number of candidate domains detected in the same tissue can vary with user-specified parameters or model-selection criteria. Whether candidate domains should be merged can be framed as a test of a single-domain null hypothesis, under which each gene has constant mean expression across all spatial units in the combined region. However, testing candidate domains on the same gene-expression data used to detect them may induce post-selection bias and yield anti-conservative p-values, increasing the risk of oversegmentation. To address these challenges, we introduce SigDoTS (statistical Significance testing for Domain deTection in Spatial transcriptomics), a hypothesis-testing framework for spatial domain detection. SigDoTS uses hierarchical testing to determine which candidate domains to retain or merge, with adjustment for family-wise error control. It accounts for gene-gene covariance and spatial dependence and computes p-values by rerunning the upstream domain-detection pipeline on datasets simulated under the fitted single-domain null. In simulations, SigDoTS controlled the type I error rate at the root node under the single-domain null and improved recovery of the true spatial domains when multiple domains were present. In human dorsolateral prefrontal cortex, SigDoTS retained superficial and deep Layer 6 domains but merged Layer 3 candidate domains across different initial numbers of candidate domains. In ovarian and colorectal cancers, SigDoTS retained epithelial domains with different gene-expression programs and local immune environments, together with immune, stromal and vascular domains.

bioinformatics↗
bioRxiv2026

ASD Neuro Agentic (ANA): An Agentic Framework for Feature Discovery and Cross Site Generalization in Autism fMRI Classification

Classifiers of autism spectrum disorder (ASD) from resting state functional MRI rarely generalize across sites, and many reported accuracies are inflated by data leakage.We show that an agentic artificial intelligence framework, ASD Neuro Agentic (ANA), whose language model agents propose features from the literature and researcher input while fixed tools perform every calculation, can search auditably for site independent classifiers while controlling the leakage. In 1,028 participants from 17 ABIDE I centers, ANA tested 71 pipelines and selected a ComBat harmonized ensemble of tangent space connectivity models from six parcellations and 98 public connectivity derivatives. In leave one center out testing, the ensemble reached an area under the curve of 0.814 (95% CI, 0.773 to 0.841), outperforming ASD DiagNet and ASD SAENet. Predictive connectivity was mainly reduced in ASD. Agentic AI offers a systematic and efficient approach to exploring, evaluating, and identifying pipelines as model selection grows complex.

bioinformatics↗